For a therapeutic approach to paclitaxel-resistant lung cancer, the EGFR inhibitor gefitinib and the PLK1 inhibitor volasertib or genistein were applied as a single reagent or combinatory reagents in parental and paclitaxel-resistant LUAD. This evidence concerns the gene PLK1 and lung carcinoma.